Astellas Pharma Inc.

OTCPK:ALPM.F Stock Report

Market Cap: US$17.8b

Astellas Pharma Valuation

Is ALPM.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALPM.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$18.35
Fair Value
43.1% undervalued intrinsic discount
15
Number of Analysts

Below Fair Value: ALPM.F ($10.44) is trading below our estimate of fair value ($18.35)

Significantly Below Fair Value: ALPM.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALPM.F?

Key metric: As ALPM.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ALPM.F. This is calculated by dividing ALPM.F's market cap by their current earnings.
What is ALPM.F's PE Ratio?
PE Ratio50.5x
EarningsJP¥50.75b
Market CapJP¥2.56t

Price to Earnings Ratio vs Peers

How does ALPM.F's PE Ratio compare to its peers?

The above table shows the PE ratio for ALPM.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.3x
RPRX Royalty Pharma
16.5x9.5%US$18.5b
JAZZ Jazz Pharmaceuticals
12.8x23.7%US$6.8b
CORT Corcept Therapeutics
56.4x42.2%US$7.5b
ZTS Zoetis
27.6x7.2%US$66.9b
ALPM.F Astellas Pharma
50.5x11.1%US$2.6t

Price-To-Earnings vs Peers: ALPM.F is expensive based on its Price-To-Earnings Ratio (50.5x) compared to the peer average (28.3x).

Price to Earnings Ratio vs Industry

How does ALPM.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
3xn/aUS$2.37b
NDOI Endo
0.3xn/aUS$1.67b
KPRX Kiora Pharmaceuticals
2.8x14.7%US$9.90m
CNNC Cannonau
0.07xn/aUS$24.18k
ALPM.F 50.5xIndustry Avg. 16.9xNo. of Companies6PE01632486480+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ALPM.F is expensive based on its Price-To-Earnings Ratio (50.5x) compared to the US Pharmaceuticals industry average (16.8x).

Price to Earnings Ratio vs Fair Ratio

What is ALPM.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALPM.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio50.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ALPM.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALPM.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$10.44
US$12.39
+18.7%
17.1%US$17.24US$8.97n/a15
May ’26US$10.12
US$12.37
+22.2%
16.9%US$17.18US$8.93n/a15
Apr ’26US$9.85
US$12.65
+28.5%
16.3%US$16.69US$9.35n/a16
Mar ’26US$10.00
US$12.96
+29.6%
15.2%US$16.78US$9.40n/a16
Feb ’26US$9.38
US$12.57
+34.1%
14.5%US$16.08US$9.00n/a16
Jan ’26US$9.86
US$12.88
+30.6%
13.3%US$16.22US$9.08n/a16
Dec ’25US$11.26
US$12.88
+14.4%
13.3%US$16.22US$9.08n/a16
Nov ’25US$11.13
US$12.91
+16.0%
12.2%US$16.31US$9.13n/a16
Oct ’25US$10.89
US$13.71
+25.9%
11.9%US$16.17US$9.85n/a16
Sep ’25US$12.21
US$13.19
+8.0%
13.1%US$15.86US$9.65n/a15
Aug ’25n/a
US$11.60
0%
14.4%US$14.62US$7.63n/a15
Jul ’25US$9.79
US$11.75
+20.1%
15.4%US$14.57US$7.60n/a15
Jun ’25US$9.77
US$12.53
+28.2%
21.2%US$20.20US$7.65n/a16
May ’25US$9.52
US$12.83
+34.7%
20.5%US$20.08US$7.60US$10.1216
Apr ’25US$11.17
US$14.34
+28.4%
20.5%US$21.22US$10.04US$9.8515
Mar ’25US$11.09
US$15.00
+35.2%
24.2%US$23.31US$9.99US$10.0015
Feb ’25US$12.05
US$16.38
+35.9%
23.2%US$23.69US$10.15US$9.3815
Jan ’25US$11.99
US$17.34
+44.7%
22.7%US$24.57US$10.53US$9.8615
Dec ’24US$12.23
US$17.65
+44.4%
19.5%US$26.44US$12.88US$11.2615
Nov ’24US$12.24
US$17.79
+45.3%
18.8%US$25.85US$13.26US$11.1315
Oct ’24US$13.96
US$18.23
+30.6%
18.6%US$25.43US$13.38US$10.8914
Sep ’24n/a
US$18.79
0%
19.8%US$26.05US$13.71US$12.2115
Aug ’24US$15.06
US$19.06
+26.6%
20.2%US$26.50US$13.25n/a15
Jul ’24US$14.71
US$19.21
+30.6%
18.9%US$25.96US$14.54US$9.7914
Jun ’24US$16.00
US$19.84
+24.0%
19.7%US$27.02US$15.13US$9.7714
May ’24n/a
US$20.18
0%
18.5%US$26.18US$16.00US$9.5212
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
US$13.10
Fair Value
20.3% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 12:15
End of Day Share Price 2025/05/07 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Astellas Pharma Inc. is covered by 29 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hazim BahariCFRA Equity Research